{"filings":[{"id":528476,"accession_number":"0001493152-26-024435","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-05-19T20:50:25+00:00","items":["5.02"],"status":"ready","headline":"Cingulate board reduces size; two directors not seeking re-election; Hargroves changes class","event_type":"leadership","confidence":"high","bullets":["Class II directors Jeff Ervin and Jay Roberts will not stand for re-election at 2026 Annual Meeting.","Board intends to reduce size to five directors and appoint a new chairman.","Jeff Hargroves resigned as Class I director and was reappointed as Class II director to maintain class balance.","Following reappointment, Class I directors are Peter Werth and Frederick Jiang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":78002,"accession_number":"0001493152-26-022881","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-05-14T12:10:16+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cingulate Q1 net loss widens to $9.3M; cash at $25.9M; CTx-1301 PDUFA May 31","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.3M for Q1 2026, up from $3.9M a year ago; G&A expenses surged to $5.7M on commercial build-out.","Cash and cash equivalents $25.9M at Mar 31, up $14.9M from Dec 31, extending runway into 2027.","FDA review of CTx-1301 NDA ongoing; PDUFA target action date remains May 31, 2026.","Commercial readiness advanced with AI-driven tools and IQVIA sales force agreement for potential launch.","R&D expenses decreased 1.8% to $2.2M as clinical studies concluded, partly offset by regulatory and CMC activities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96364,"accession_number":"0001493152-26-014914","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cingulate appoints Frederick Jiang to Board; grants 15,000-share option","event_type":"leadership","confidence":"high","bullets":["Zhanpeng 'Frederick' Jiang appointed Class I director effective March 27, 2026.","He will serve on Audit, Compensation, and Nominating Committees; deemed independent.","Granted option to purchase 15,000 shares vesting over 1 year in two installments.","Annual cash retainers: $40,000 for Board plus $7,500 Audit, $5,000 Compensation, $4,000 Nominating.","Appointment follows stockholder approval of a prior securities purchase agreement (Jan 28, 2026)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110216,"accession_number":"0001493152-26-012417","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["1.01","5.07"],"status":"ready","headline":"Cingulate enters $100M at-the-market equity facility with A.G.P.","event_type":"other_material","confidence":"high","bullets":["Entered ATM Sales Agreement with A.G.P./Alliance Global Partners for up to $100M gross proceeds.","Company may sell shares at-the-market on Nasdaq; A.G.P. receives 3.0% commission.","Stockholders approved issuance of common stock upon conversion of Series A Preferred and warrant exercise.","Special Meeting approval clears Nasdaq Listing Rule 5635(b) requirement for prior issuance.","Adjournment proposal also passed but not needed as sufficient votes obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110215,"accession_number":"0001493152-26-010881","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Cingulate reports $22.4M FY2025 net loss, CTx-1301 patent allowed, PDUFA May 2026","event_type":"other_material","confidence":"high","bullets":["Net loss of $22.4M for 2025 vs $16.6M in 2024; Q4 net loss $6.3M.","Cash $11.0M at Dec 31, 2025; expects runway into late Q4 2026.","USPTO Notice of Allowance for CTx-1301 patent; protection through May 2042.","NDA for CTx-1301 accepted under 505(b)(2); PDUFA target date May 31, 2026.","Closed $12M at-the-market PIPE in Feb 2026 led by Falcon Creek Capital; 180-day lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110214,"accession_number":"0001493152-26-006942","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["3.02","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Cingulate closes $12M PIPE financing, appoints Jeff Hargroves to board and converts debt","event_type":"other_material","confidence":"high","bullets":["Cingulate completed $12M private placement led by Falcon Creek Capital at $5.04 per share with 80% warrant coverage","Jeff Hargroves appointed as Class I director and to Audit, Compensation, and Nominating committees","Company issued 25,786 shares at $6.16 per share to a lender in exchange for debt under Section 3(a)(9)","All PIPE investors subject to 180-day lock-up; total potential proceeds up to $21.4 million","FDA PDUFA target date for CTx-1301 ADHD treatment set for May 31, 2026"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110213,"accession_number":"0001493152-26-005561","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Cingulate closes $6.5M private placement tranche; issues shares for debt","event_type":"other_material","confidence":"high","bullets":["Completed portion of private placement for gross proceeds of $6.5M on Feb 6, 2026; remaining $5.5M expected to close soon.","Issued 361,409 shares to a lender from Jan 6 to Feb 5, 2026, in exchange for debt, at prices from $4.35 to $6.01 per share.","All issuances were exempt from registration under Section 3(a)(9) of the Securities Act.","Private placement was previously announced in Form 8-K dated January 28, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110212,"accession_number":"0001493152-26-004030","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["1.01","3.02","5.03","9.01"],"status":"ready","headline":"Cingulate raises ~$12M in private placement of common stock, preferred, and warrants","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$12M; issues 2.15M common shares, 973 shares Series A preferred at $1,000 stated value, and warrants for 1.87M shares.","Purchase price $5.14 per common share (includes $0.10 per warrant share); conversion/exercise price $5.04.","Series A preferred carries 12% cumulative annual dividend; conversion requires stockholder approval.","Falcon Creek (manager of lead investor) may designate two directors after stockholder approval.","Proceeds used for working capital and general corporate purposes; 180-day lock-up and 24-month standstill."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110211,"accession_number":"0001493152-26-002417","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Cingulate ups ATM offering by $8.4M to $31.94M, files new prospectus supplement","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate offering price increased from $23,536,658 to $31,936,658 under ATM with H.C. Wainwright.","New prospectus supplement covers $8,840,000 of common stock issuable under the Sales Agreement.","Prior to Jan 12, 2026, the company had sold $15,145,503.74 of common stock under the ATM.","Legal opinion from Lowenstein Sandler LLP on the newly registered shares filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110210,"accession_number":"0001493152-26-000142","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2026-01-02T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Cingulate issues 426,853 shares to lenders through debt conversion from Nov 21 to Jan 2","event_type":"debt","confidence":"high","bullets":["Issued shares in six tranches between Nov 21, 2025 and Jan 2, 2026 to settle debt.","Share prices ranged from $3.39 to $4.13 per share; total ~$1.65M of debt exchanged.","All issuances exempt from registration under Section 3(a)(9) of the Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126770,"accession_number":"0001493152-25-027667","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO Shane Schaffer reinstated after no-contest plea; amended employment agreement modified severance","event_type":"leadership","confidence":"high","bullets":["Shane Schaffer reinstated as CEO Dec 15, 2025, after administrative leave; pled no contest to misdemeanor, received 12 months probation.","Amended employment agreement: base salary reinstated; 'Cause' definition expanded to include probation violation; board vote reduced to majority.","Severance modified: lump sum lowered to 1x base+bonus (without cause/good reason) and 1.5x base+bonus (change in control).","John Roberts ends Executive Chairman role but remains Chairman; Jennifer Callahan continues as CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126769,"accession_number":"0001493152-25-022132","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cingulate Q3 net loss $7.3M widens 78% YoY; NDA for CTx-1301 accepted with PDUFA May 31, 2026","event_type":"earnings","confidence":"high","bullets":["Net loss $7.3M vs $4.1M in Q3 2024; operating loss $6.0M on R&D $2.8M (+99.5% YoY) and G&A $3.1M (+69.7%).","Cash $6.1M at Sep 30, 2025; company says it needs ~$7M additional capital to fund through May 2026 PDUFA.","FDA accepted NDA for ADHD drug CTx-1301; PDUFA target date May 31, 2026; $4.3M fee waiver granted.","Appointed Bryan Downey as CCO; closed $6M promissory note financing with 9% interest, maturing 18 months.","Commercial supply agreement with Bend Bio Sciences for exclusive U.S. manufacture of CTx-1301 through 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126768,"accession_number":"0001493152-25-021410","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"Cingulate completes $6M debt financing, appoints Bryan Downey as CCO","event_type":"other_material","confidence":"high","bullets":["Issued $6.57M unsecured promissory note at 9% interest, maturing 18 months, to Avondale Capital for $6M net proceeds.","Bryan Downey appointed Chief Commercial Officer; granted 30,000 options at $3.80/share, vesting over 4 years.","Cash runway extended into Q2 2026; proceeds for working capital and general corporate purposes.","FDA accepted NDA for CTx-1301 (ADHD); PDUFA target action date May 31, 2026.","Note includes monthly redemption up to $660k after PDUFA; company can defer up to 2 redemptions with 1% fee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126767,"accession_number":"0001493152-25-017931","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA accepts Cingulate's NDA for CTx-1301 in ADHD; PDUFA date May 31, 2026","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for CTx-1301 (dexmethylphenidate), a once-daily PTR stimulant for ADHD in children and adults, under 505(b)(2) pathway.","PDUFA target action date is May 31, 2026; acceptance confirms submission sufficiently complete for substantive review.","Phase 3 trials showed large effect sizes on PERMP, AISRS, ADHD-RS-5, CGI scales; no serious treatment-emergent adverse events.","Commercial readiness: process transfer and scale-up completed with Bend Bio Sciences; AI-driven omnichannel platform with Indegene launched.","Early payer research indicates strong formulary receptivity for once-daily CTx-1301, aligning with adherence priorities in ADHD care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143561,"accession_number":"0001493152-25-014963","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Cingulate shareholders approve issuance of >20% stock to Lincoln Park Capital","event_type":"other_material","confidence":"high","bullets":["Approved issuance of >20% of common stock to Lincoln Park Capital Fund, LLC under purchase agreement.","Vote results: 1,597,394 For, 213,885 Against, 9,561 Abstain; no broker non-votes.","Adjournment proposal approved but not needed due to sufficient votes for the Issuance Proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143560,"accession_number":"0001493152-25-012753","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-09-05T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Cingulate issues 325,729 shares to lenders in debt-for-equity swaps","event_type":"other_material","confidence":"high","bullets":["July 30: 58,139 shares at $5.16 per share issued to lender for debt reduction.","August 12: 74,074 shares at $4.05 per share issued to lender.","August 21: 64,102 shares at $3.90 per share issued to lender.","August 29: 63,451 shares at $3.94 per share; Sept 5: 65,963 at $3.79 per share.","All issuances exempt under Section 3(a)(9) of Securities Act as exchanges with existing holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143559,"accession_number":"0001493152-25-012449","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cingulate sets exec chairman retainer at $10K/mo; CEO on leave at 75% pay; ex-exec Myers gets $436K severance","event_type":"leadership","confidence":"high","bullets":["John A. Roberts appointed Executive Chairman effective Aug 14; receives $10,000/month cash retainer.","CEO Shane Schaffer on administrative leave; salary reduced to 75% with benefits continued.","Laurie Myers employment ended Aug 7; Separation Agreement signed Aug 28 for $436,720 severance paid over 12 months.","Myers' unvested stock options fully vest and remain exercisable; post-employment restrictions including non-disparagement apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143558,"accession_number":"0001641172-25-024741","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Cingulate Q2 net loss widens to $4.8M; files NDA for CTx-1301 with FDA","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.8M in Q2 2025, up from $3.2M in Q2 2024; R&D spend +43.6% to $2.7M.","Cash and cash equivalents $8.9M as of June 30, 2025; expects cash needs into late 2025; needs ~$1.5M more for commercialization.","Submitted NDA to FDA for lead asset CTx-1301 (dexmethylphenidate) on July 31, 2025; FDA decision on acceptance expected in 60 days.","Executed $25M purchase agreement with Lincoln Park Capital for at-the-market common stock sales over 36 months.","Phase 3 pediatric study showed marked improvement in ADHD symptoms at week five."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143557,"accession_number":"0001641172-25-024286","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cingulate CEO Shane Schaffer charged with aggravated domestic battery; placed on administrative leave","event_type":"leadership","confidence":"high","bullets":["CEO Shane Schaffer charged with one count of aggravated domestic battery on August 9, 2025.","Board placed Dr. Schaffer on administrative leave on August 14, 2025, pending legal resolution.","CFO Jennifer Callahan appointed interim CEO, continuing as CFO until further Board action.","Director John A. Roberts appointed Executive Chairman to provide operational support to management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143556,"accession_number":"0001641172-25-022664","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Cingulate terminates EVP/COO Laurie A. Myers on August 7, 2025","event_type":"leadership","confidence":"high","bullets":["Laurie A. Myers, Executive Vice President and Chief Operating Officer, terminated.","Effective date of termination: August 7, 2025.","No successor or interim replacement announced; no reason provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143555,"accession_number":"0001641172-25-022360","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Cingulate submits NDA to FDA for lead ADHD drug CTx-1301","event_type":"regulatory","confidence":"high","bullets":["Submitted NDA on July 31, 2025 for CTx-1301 (dexmethylphenidate) for ADHD.","FDA will decide on acceptance within 60 days of July 31 submission.","Drug designed as novel extended-release tablet for once-daily, entire active-day symptom control.","Cingulate targets $23B U.S. ADHD market; over 20M patients diagnosed in US.","NDA is first regulatory application of company's proprietary Precision Timed Release platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143554,"accession_number":"0001641172-25-021006","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Cingulate issues 144,063 common shares and 30,000 option in unregistered sales from Mar 31 to Jul 21","event_type":"other_material","confidence":"high","bullets":["Issued 7,538 shares at $4.36/share to a service provider on May 12, 2025.","Issued 73,068 shares at $4.79/share to a lender for debt reduction on July 21, 2025; additional debt exchanges of 5,986 and 57,471 shares on July 10 and 14 at $4.18 and $4.35/share.","Granted officer option to buy 30,000 shares at $4.51, vesting over 4 years with 25% after one year.","All issuances exempt under Securities Act Sections 4(a)(2) or 3(a)(9)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143553,"accession_number":"0001641172-25-020618","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Cingulate enters $25M equity purchase agreement with Lincoln Park Capital","event_type":"other_material","confidence":"high","bullets":["Lincoln Park Capital commits to buy up to $25M of Cingulate common stock over 36 months, starting after SEC registration effective.","Cingulate issued 120,424 commitment shares to Lincoln Park on July 21, 2025 as consideration for the commitment.","Sales are at Cingulate's discretion with a single-day cap of $150K (up to $500K depending on price) and an Exchange Cap of 1,004,660 shares (19.99% of outstanding).","Proceeds intended for regulatory approval and development of CTx-1301, plus working capital and R&D.","Lincoln Park is barred from short sales or hedging during the term; Cingulate may terminate with one business day notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161750,"accession_number":"0001641172-25-014621","cik":1862150,"company_name":"Cingulate Inc.","ticker":"CING","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Cingulate stockholders approve reverse stock split (1:2 to 1:25) and equity plan share increase to 1,141,826","event_type":"other_material","confidence":"high","bullets":["Stockholders authorized a reverse stock split at a ratio between 1:2 and 1:25, to be determined by board before June 10, 2026.","Equity plan shares increased by 800,000 to 1,141,826, approved by 606,730 votes for vs 165,846 against.","Peter J. Werth elected as Class I director for term ending 2028, with 732,644 votes for.","KPMG LLP ratified as independent auditor for 2025, with 2,434,032 votes for.","Adjournment proposal deemed unnecessary; all proposals passed with sufficient votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}